Hypersensitivity
3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
GSKLONDON, United Kingdom
2 programs1
Mometasone furoate drug formulationPhase 11 trial
Carvedilol immediate release onlyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BayerButenafine HCl 1%
Allergy TherapeuticsEgg oral immunotherapy
GSKMometasone furoate drug formulation
GSKCarvedilol immediate release only
Clinical Trials (4)
Total enrollment: 306 patients across 4 trials
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
Start: Sep 2013Est. completion: Oct 2013225 patients
Phase 3Completed
Oral Immunotherapy for Childhood Egg Allergy
Start: May 2007Est. completion: Dec 2013
Phase 2Completed
Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays
Start: Sep 2018Est. completion: Apr 202180 patients
Phase 1Completed
Coreg and HSRs-Updated Analysis
Start: Jun 2010Est. completion: Mar 20111 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space